- Investing Ideas
- /
- Biotech Breakthroughs
Biotech Breakthroughs
UPDATED Apr 08, 2024
Companys with strong funding and high growth potential
53 companies
| Company | Last Price | 7D Return | 1Y Return | Market Cap | Analysts Target | Valuation | Growth | Div Yield | Industry | ||
|---|---|---|---|---|---|---|---|---|---|---|---|
BOVN.F | kr4.70 | 0% | n/a | kr2.7b | kr12.58 | PS9.2x | E62.0% | n/a | Pharmaceuticals & Biotech | ||
GTHX | US$4.77 | 4.8% | 90.8% | US$249.5m | US$8.50 | PS3x | E55.1% | n/a | Pharmaceuticals & Biotech | ||
RCEL | US$15.13 | -2.7% | 2.3% | US$396.7m | US$26.49 | PS7.8x | E64.0% | n/a | Pharmaceuticals & Biotech | ||
SGEN | US$228.74 | 4.5% | 76.5% | US$43.2b | US$228.91 | PS18.8x | E71.8% | n/a | Pharmaceuticals & Biotech | ||
IMGN | US$31.23 | 6.6% | 617.9% | US$8.4b | US$28.95 | PS29.1x | E45.8% | n/a | Pharmaceuticals & Biotech | ||
IPHY.F | €2.65 | 2.7% | n/a | €189.2m | €7.54 | PS2.9x | E30.0% | n/a | Pharmaceuticals & Biotech | ||
AVHH.L | US$3.20 | 0% | 28.0% | US$396.7m | US$5.60 | PS7.8x | E64.0% | n/a | Pharmaceuticals & Biotech | ||
IVVD | US$3.06 | -28.0% | 155.0% | US$393.4m | US$9.38 | PB2.1x | E64.5% | n/a | Pharmaceuticals & Biotech | ||
ARDX | US$7.32 | -1.2% | 71.8% | US$1.7b | US$13.39 | PS13.7x | E59.6% | n/a | Pharmaceuticals & Biotech | ||
MIRM | US$25.92 | 1.8% | 3.8% | US$1.2b | US$49.00 | PS6.5x | E63.2% | n/a | Pharmaceuticals & Biotech | ||
IPHA | €2.60 | -3.0% | -18.5% | €189.2m | €6.97 | PS3.1x | E30.0% | n/a | Pharmaceuticals & Biotech | ||
ISEE | US$39.95 | 0.9% | 236.3% | US$5.5b | US$40.00 | PB11.6x | E59.0% | n/a | Pharmaceuticals & Biotech | ||
SPRY | US$9.93 | 4.9% | 68.9% | US$952.5m | US$19.00 | PS31942x | E56.2% | n/a | Pharmaceuticals & Biotech | ||
CAPR | US$6.58 | -7.3% | 55.2% | US$211.7m | US$21.00 | PS8.2x | E59.4% | n/a | Pharmaceuticals & Biotech | ||
ABEO | US$7.52 | -2.6% | 165.7% | US$203.5m | US$21.00 | PS58.8x | E60.7% | n/a | Pharmaceuticals & Biotech | ||
MGTX | US$5.57 | -4.1% | 4.7% | US$353.2m | US$21.60 | PS25.5x | E52.8% | n/a | Pharmaceuticals & Biotech | ||
MDGL | US$248.64 | -2.8% | 1.3% | US$5.1b | US$394.54 | PB12.9x | E62.2% | n/a | Pharmaceuticals & Biotech | ||
ACAD | US$17.80 | -2.5% | 0% | US$3.0b | US$29.64 | PS4x | E41.8% | n/a | Pharmaceuticals & Biotech | ||
SRPT | US$126.98 | -0.02% | -8.7% | US$11.9b | US$164.59 | PS9.6x | E42.3% | n/a | Pharmaceuticals & Biotech | ||
BEIG.F | US$14.29 | 0% | n/a | US$15.1b | US$27.99 | PS6.8x | E52.9% | n/a | Pharmaceuticals & Biotech | ||
MEOB.F | AU$0.60 | 39.5% | n/a | AU$1.1b | n/a | PS93.2x | E64.4% | n/a | Pharmaceuticals & Biotech | ||
GNFT | €3.46 | -2.8% | -8.3% | €160.1m | €10.08 | PS4.2x | E55.8% | n/a | Pharmaceuticals & Biotech | ||
PGEN | US$1.41 | -1.4% | 36.9% | US$348.5m | US$9.00 | PS56.4x | E55.5% | n/a | Pharmaceuticals & Biotech | ||
PRRU.F | AU$0.24 | 0% | n/a | AU$487.4m | n/a | PS122.5x | E60.3% | n/a | Pharmaceuticals & Biotech |